For how we live.
The LEAP trial found that feeding peanut to high-risk babies from infancy cut peanut allergy at age five from 13.7% to 1.9%. A follow-up showed the protection held — but high-risk infants should be assessed first.
In the 2,137-participant PrEggNut trial, mothers who ate a diet rich in eggs and peanuts through pregnancy and breastfeeding had infants with the same allergy rate as the comparison group.
Hospital admissions for food anaphylaxis in the UK rose 5.7% a year for two decades while the case fatality rate fell. The treatment recommendations have almost no randomised evidence behind them.
A European allergy task force concluded the antibody these tests detect is a marker of tolerance, not hypersensitivity. Meanwhile 19% of US adults believe they have a food allergy and about 10.8% have one.
The LEAP trial cut peanut allergy in high-risk infants from 13.7% to 1.9%. A second trial found the benefit real but harder to achieve — and only in children who actually ate the food.
The LEAP trial reversed a generation of avoidance advice. A second trial run in the general population missed its primary endpoint, and the distance between those two results is the part usually left out.